Uncategorized

Cerecin forges strategic partnership with A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders.

Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding with A*STAR’s Institute of Molecular and Cell Biology.

Cerecin forges strategic partnership with A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders. Read More »

Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023

Innovent Biologics, Inc. announces the publication of updated clinical data of IBI351 monotherapy in non-small cell lung cancer and colorectal cancer at the European Society for Medical Oncology Asia Congress 2023, held during December 1-3 in Singapore.

Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023 Read More »

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

HUTCHMED Limited highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug candidates fruquintinib, surufatinib and HMPL-295, which will be presented at the upcoming European Society for Medical Oncology Asia Congress, taking place on December 1-3, 2023 in Singapore, and the ESMO Immuno-Oncology Congress, taking place on December 6-8, 2023 in Geneva,

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses Read More »

Scroll to Top